Objective:To explore the factors of clinical disease progression in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) cirrhosis, and to construct a risk prediction model.Methods:A total of 395 HBeAg-negative CHB cirrhosis patients admitted to Handan Infectious Disease Hospital from March 2018 to December 2023 were retrospectively selected, and disease progression (follow-up up to February 2024) was taken as the end event. Among them, 113 patients developed disease progression (progression group) and 282 patients did not develop disease progression (non-progression group). Univariate and multivariate Logistic regression were used to analyze the risk factors for clinical disease progression in patients with HBeAg-negative CHB cirrhosis, and a nomogram risk prediction model was constructed. Calibration curve, receiver operating characteristic (ROC) curve and decision curve analysis (DCA) were used to verify the efficacy of the model.Results:The results of single factor analysis showed that age, family history of liver disease, alcohol consumption history, Child-Pugh rating, hypertension, model of end-stage liver disease (MELD) score, portal vein diameter, hepatitis B virus-DNA (HBV-DNA) measurement, albumin (ALB), spleen vein diameter, total bilirubin (TBIL), blood sodium, hemoglobin (Hb), blood ammonia, and white blood cell count (WBC), international normalized ratio (INR), liver stiffness measurement (LSM) and C-reactive protein (CRP) were the factors that affected clinical disease progression ( P<0.05). Logistic regression analysis showed that drinking history, Child-Pugh grade, MELD score, portal vein diameter, HBV-DNA quantification, splenic vein diameter, LSM, ALB, Hb and CRP were independent risk factors affecting clinical disease progression ( OR = 3.537, 6.407, 1.554, 1.658, 8.090, 1.681, 1.539, 0.382, 0.232, 1.924, P<0.05). The calibration curve showed that the prediction ability of the model was high, the ROC curve showed that the area under the curve (AUC) predicted by the model was 0.869 - 0.941, and the result of the DCA showed that the model had a high positive benefit. Conclusions:The influencing factors of clinical disease progression in HBeAg-negative CHB cirrhosis patients include alcohol consumption history, Child-Pugh grade, MELD score, portal vein diameter, HBV-DNA quantification, splenic vein diameter, LSM value, ALB, Hb and CRP. The risk early warning model based on the above factors has good predictive efficacy and clinical application efficacy.

Objective:To explore the factors of clinical disease progression in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) cirrhosis, and to construct a risk prediction model.Methods:A total of 395 HBeAg-negative CHB cirrhosis patients admitted to Handan Infectious Disease Hospital from March 2018 to December 2023 were retrospectively selected, and disease progression (follow-up up to February 2024) was taken as the end event. Among them, 113 patients developed disease progression (progression group) and 282 patients did not develop disease progression (non-progression group). Univariate and multivariate Logistic regression were used to analyze the risk factors for clinical disease progression in patients with HBeAg-negative CHB cirrhosis, and a nomogram risk prediction model was constructed. Calibration curve, receiver operating characteristic (ROC) curve and decision curve analysis (DCA) were used to verify the efficacy of the model.Results:The results of single factor analysis showed that age, family history of liver disease, alcohol consumption history, Child-Pugh rating, hypertension, model of end-stage liver disease (MELD) score, portal vein diameter, hepatitis B virus-DNA (HBV-DNA) measurement, albumin (ALB), spleen vein diameter, total bilirubin (TBIL), blood sodium, hemoglobin (Hb), blood ammonia, and white blood cell count (WBC), international normalized ratio (INR), liver stiffness measurement (LSM) and C-reactive protein (CRP) were the factors that affected clinical disease progression ( P<0.05). Logistic regression analysis showed that drinking history, Child-Pugh grade, MELD score, portal vein diameter, HBV-DNA quantification, splenic vein diameter, LSM, ALB, Hb and CRP were independent risk factors affecting clinical disease progression ( OR = 3.537, 6.407, 1.554, 1.658, 8.090, 1.681, 1.539, 0.382, 0.232, 1.924, P<0.05). The calibration curve showed that the prediction ability of the model was high, the ROC curve showed that the area under the curve (AUC) predicted by the model was 0.869 - 0.941, and the result of the DCA showed that the model had a high positive benefit. Conclusions:The influencing factors of clinical disease progression in HBeAg-negative CHB cirrhosis patients include alcohol consumption history, Child-Pugh grade, MELD score, portal vein diameter, HBV-DNA quantification, splenic vein diameter, LSM value, ALB, Hb and CRP. The risk early warning model based on the above factors has good predictive efficacy and clinical application efficacy.

OBJECTIVETo understand the distribution of virulence gene and the epidemiological characteristics of diarrheagenic Escherichia(E.) coli (DEC) from diarrheal patients in Beijing.

METHODSStool specimens from diarrheal patients were cultured which were collected from the hospitals under sentinel surveillance program, during 2012-2013. DNA was examined by real-time PCR.

RESULTS253 out of 6 370 specimens were positive for DEC detection with the rate as 4.0%. A total number of 262 DEC strains were isolated. Two different pathotypes of DEC strains with mixed infection, were isolated from 9 specimens. Different pathotypes would show the following profiles: 42.8% for enteropathogenic E. coli (EPEC) including 42.0% atypical and 0.8% typical; 38.9% for enterotoxigenic E. coli (ETEC) including 24.8% st positive, 9.9% lt positive and 4.2% st and lt both positive;15.3% for enteroaggregative E. coli(EAEC);2.7% for enteroinvasive E. coli (EIEC); one strain STEC with serotype O26:K60. ETEC had obvious characteristics on age. All kinds of DEC were isolated throughout the year with seasonal fluctuation.

CONCLUSIONDEC isolates from diarrheal patients in Beijing were dominated by EPEC and ETEC, with atypical ones accounted for the majority of EPEC. One specimen was found under mixed infection. Pathotypes DEC were found to have different age and seasonal distributions.

China ; epidemiology ; Diarrhea ; microbiology ; Enteropathogenic Escherichia coli ; genetics ; isolation & purification ; Enterotoxigenic Escherichia coli ; genetics ; isolation & purification ; Epidemics ; Escherichia coli ; genetics ; isolation & purification ; Escherichia coli Infections ; epidemiology ; microbiology ; Genotype ; Humans ; Virulence

Objective To understand the distribution of virulence gene and the epidemiological characteristics of diarrheagenic Escherichia(E.) coli (DEC) from diarrheal patients in Beijing. Methods Stool specimens from diarrheal patients were cultured which were collected from the hospitals under sentinel surveillance program,during 2012-2013. DNA was examined by real-time PCR. Results 253 out of 6 370 specimens were positive for DEC detection with the rate as 4.0%. A total number of 262 DEC strains were isolated. Two different pathotypes of DEC strains with mixed infection,were isolated from 9 specimens. Different pathotypes would show the following profiles:42.8% for enteropathogenic E. coli (EPEC) including 42.0% atypical and 0.8% typical;38.9% for enterotoxigenic E. coli(ETEC)including 24.8%st positive,9.9%lt positive and 4.2%st and lt both positive;15.3% for enteroaggregative E. coli(EAEC);2.7% for enteroinvasive E. coli(EIEC);one strain STEC with serotype O26 ∶ K60. ETEC had obvious characteristics on age. All kinds of DEC were isolated throughout the year with seasonal fluctuation. Conclusion DEC isolates from diarrheal patients in Beijing were dominated by EPEC and ETEC,with atypical ones accounted for the majority of EPEC. One specimen was found under mixed infection. Pathotypes DEC were found to have different age and seasonal distributions.

Objective To discuss the influence of Yifei-Kangxin capsule on MMP-1 in Wistar rats model with pulmonary heart disease. Methods 40 Wistar rats with pulmonary heart disease were averagely grouped as Normal Group, Model Group, Therapeutic Group and Comparative Group randomly by weight. The rats in Therapeutic Group were given Yifei-Kangxin capsule and the rats in Comparative Group were given Nifedipine. The course of treatment was 15 days. The rats were killed at the next 7th, 14th and 28th day separately to test MMP-1 in pulmonary tissue. Results After the treatment, the expression of MMP-1 in pulmonary tissue of the Therapeutic Group[7 d, 14 d, 28 d was(0.231±0.017)ng/m、(0.308±0.081)ng/m、(0.358±0.074)ng/m]was lower than the Model Group[7 d, 14 d, 28 d was(0.266±0.036)ng/m 、(0.315± 0.060)ng/m、(0.612±0.091)ng/m]. Conclusion Yifei-Kangxin capsule can inhibit the expression of MMP-1 in the rats model pulmonary heart disease.